Patients with ECOG performance status @ to @ and clinical decision to treat with bisphosphonates within @ months of randomisation were randomly assigned to receive @ weeks of treatment with either intravenous zoledronic acid at @ mg every @-@ weeks or oral ibandronic acid @ mg daily .